The company said it was restarting production of its baby formula. The Abbott manufacturing facility is pictured in the picture. Two infants died and two others became sick after consuming formula produced in the plant and Abbott initiated a voluntary recall. The photo was taken by JEFF KOWALSKY/ Agence France-Presse.
The company announced Saturday that it had resumed production of a specialty brand of infant formula at its facility in Michigan.
The product being produced once again isn't expected to be available to consumers for another fortnight. There were supply problems across the U.S. when a large factory was shut down in February.
The first EleCare product will be available to consumers on or about June 20. As soon as we can, we will restart production of Similac and other formulas.
The shutdown of the Michigan plant has led to a nationwide shortage of infant formula, particularly the more popular Similac that has been a flagship brand of Abbott's. The production of EleCare is important because of the formula's ability to be used by infants and children.
The top priority of Abbott is to get high-quality, safe formula into the hands of families. While meeting all requirements, we will ramp production as soon as possible. We are committed to safety and quality and will do everything we can to regain the trust of parents, caregivers and health care providers.
Abbott has said its products haven't been directly linked to infections in infants who consumed formula produced at the plant.
The state, FDA, and/or CDC tested samples of the Abbott formula that was used by the child. All of the containers were negative.
All Rights Reserved © 2024
